关于抗高血压药物的门德尔随机化研究的系统综述
Bohan Fan1, Junmeng Zhang1, Jie V Zhao2,3
1School of Public Health, Li Ka Shing, Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
BMC medicine
|November 20, 2024
概括
门德尔随机化研究表明,抗高血压药物,如ACE抑制剂,有利于心血管健康和糖尿病,但可能对其他疾病构成风险. 需要进一步的研究以随机对照试验来证实这些发现.
科学领域:
- 药物基因组学 药物基因组学
- 药物的有效性和安全性.
- 系统审查方法论 系统审查方法论
背景情况:
- 抗高血压药物被广泛用于管理高血压.
- 了解不同药物类别对健康的广泛影响对于优化患者护理至关重要.
- 门德尔随机化 (MR) 提供了一个强大的工具来调查药物标和健康结果之间的因果关系.
研究的目的:
- 对抗高血压药物的门德尔随机化研究进行系统审查.
- 总结有关各种抗高血压药物类别对健康的影响的证据.
- 将MR发现与现有的随机对照试验 (RCT) 证据进行比较.
主要方法:
- 在PubMed和Embase上对MR研究进行全面的文献搜索,直到2024年5月.
- 提取和综合研究特征,结果和质量的数据.
- 对MR证据与随机对照试验 (RCT) 数据进行比较分析.
主要成果:
- 包括37项MR研究,检查了广泛的健康结果.
- 强有力的证据支持抗高血压药物对心血管疾病的保护作用.
- ангиотензин转化酶 (ACE) 抑制剂对糖尿病有好处,但对牛皮和神经退行性疾病有潜在风险;β-抑制剂表明不良影响.
- ACE 抑制剂和通道阻断剂 (CCB) 对脏和免疫功能有明显的益处,CCB 显示在妊娠障碍中安全.
结论:
- MR提供了对抗高血压药物的有益和潜在的非目标效应的宝贵见解.
- 结果可以为临床决策提供信息,增强药物监督,并确定药物重新用途的机会.
- 虽然MR表明对中风,糖尿病和功能等疾病有好处,但对许多结果需要进一步的RCT验证.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
386
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
386
01:25Antihypertensive Drugs: Direct Renin Inhibitors
493
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
493
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
590
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
590
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
479
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
479
01:28Antihypertensive Drugs: Types of β-Blockers
586
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
586
01:23Antihypertensive Drugs: Vasodilators
479
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
479